false
0001878313
0001878313
2024-03-05
2024-03-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 5, 2024
MAIA
Biotechnology, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-41455 |
|
83-1495913 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
| 444
West Lake Street, Suite 1700 |
|
|
| Chicago,
IL |
|
60606 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
(312)
416-8592
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock |
|
MAIA |
|
NYSE
American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
On
March 5, 2024, MAIA Biotechnology, Inc. (the “Company”) issued a 2024 Letter to Shareholders detailing the Company’s
immuno-oncology cancer treatment candidates and development pipeline.
A
copy of the 2024 Letter to Shareholders is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
On
March 5, 2024, the Company issued a press release announcing the release of the 2024 Letter to Shareholders detailing the Company’s
immuno-oncology cancer treatment candidates and development pipeline
A
copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Forward-looking
Statements
The
Company cautions that all statements, other than statements of historical facts, contained in this Current Report on Form 8-K, or furnished
herewith, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other
factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different
from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,”
“could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,”
“project,” “intend,” “future,” “potential,” or “continue,” and other similar
expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are
not forward-looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that,
although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as
to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However,
these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control
that may cause actual results to differ materially from those expressed in any forward-looking statement, including, but not limited
to: (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs,
(ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory
filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing
process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for
our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain
intellectual property protection for our product candidates. Any forward-looking statement speaks only as of the date on which it was
made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information,
future events or otherwise, except as required by law.
| Item
9.01. |
Financial
Statements and Exhibits. |
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
March 6, 2024
| |
MAIA
BIOTECHNOLOGY, INC. |
| |
|
|
| |
By:
|
/s/
Vlad Vitoc |
| |
Name:
|
Vlad
Vitoc |
| |
Title:
|
Chief
Executive Officer |
Exhibit 99.1
March
2024
Dear
fellow shareholders,
At
MAIA Biotechnology, our tenacious pursuit of innovative medicines to improve and extend people’s lives with cancer has led us to
the forefront of cancer research. As we wrap up the Phase 2 clinical trial of our lead molecule THIO in non-small cell lung cancer (NSCLC)
and pursue additional indications and a pipeline of next-generation THIO-like molecules, we are creating a robust
and transformational cancer treatment franchise.
Our
groundbreaking work explores a new science for cancer therapy utilizing a novel dual mechanism of action: telomere targeting and immunogenicity.
We are developing THIO as a second line or later treatment for NSCLC patients who have progressed beyond standard-of-care regimens. The
telomere-centric action of THIO is being evaluated in THIO-101, a Phase 2 go-to-market clinical trial of THIO sequenced with the immune
checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in advanced NSCLC patients. Throughout the trial, the pace of enrollment has exceeded
the average pace in similar NSCLC trials, and we completed our target enrollment earlier than expected on February 19, 2024.
Preliminary
THIO-101 data reported to date has shown unprecedented disease control rates in second-line and third-line treatment that outperform
the standard of care. We are expecting updated third-line data during the current quarter of 2024 and anticipate topline data in the
second half of this year. We expect that THIO-101 will be the first completed clinical study of a telomere targeting agent in the field
of cancer drug discovery and treatment.
Investigational
THIO
Telomerase
is present in 85% to 90% of human cancers and contributes significantly to the proliferation and reproductive immortality of cancer cells.
THIO is a small molecule telomere targeting anticancer agent that acts by producing direct telomeric DNA damage and inducing cancer-specific
immune responses. THIO’s action in cancer treatment has been featured in multiple renowned scientific publications, such as Cancer
Cell and Nature.
Our
preclinical findings show that THIO works against difficult-to-treat tumor types that are generally unresponsive to CPI immunotherapy
alone. In preclinical testing, THIO was proven curative in combination with immunotherapy checkpoint inhibitors, such as Libtayo®
(Regeneron), Keytruda® (Merck), and Tecentriq® (Roche/Genentech) in multiple tumor types: lung, colorectal, liver, and brain
cancers. These results were achieved at doses approximately 40 times under the maximum tolerated dose. Such an efficacy/safety profile
is unprecedented in oncology. The U.S. Food and Drug Administration (FDA) has reviewed and endorsed the data, awarding THIO three Orphan
Drug Designations (ODD): hepatocellular carcinoma (the dominant histology of primary liver cancers, ~90%), small cell lung cancer (the
deadliest type of lung cancer), and malignant gliomas (the deadliest group of brain cancers, including glioblastomas). With each ODD
we can benefit from seven years of U.S. market exclusivity after drug approval and tax credits for qualified clinical testing.
The
leading checkpoint inhibitors in the market currently account for over $37 billion in global annual sales combined1. As
a whole, the checkpoint inhibitor class is forecasted to reach $148 billion globally by 20302. THIO would work very well
with any of the CPIs.
1
Company research
2
BioSpace, Immune Checkpoint Inhibitors Market Size
THIO-101
Phase 2 Clinical Trial
The
THIO-101 trial has two primary objectives: 1) to evaluate the safety and tolerability of THIO administered as an anticancer compound
and an activator of the human immune system, and 2) to assess the clinical efficacy of THIO. As part of the trial design, we tested
three different doses, and we selected the most efficacious dose of THIO 180mg in November 2023.
Since
THIO-101’s beginning in 2022, we are strongly encouraged that patients in our study are receiving benefit long after discontinuing
therapy, with no new anti-cancer treatments initiated. The safety profile of THIO has shown to be far better than the standard of care,
chemotherapy3.
Long-term
survival for the first two subjects dosed in the trial (both receiving third-line treatment) is 14.6 and 12.5 months as of our latest
published data. In real-world clinical practice, similarly heavily pretreated patients expected survival without treatment is only 3
to 4 months.
THIO
Indications
Non-small
cell lung cancer is the largest tumor type globally by mortality (1.7 million deaths annually) and dollar sales ($34 billion annually).
It is an insidious disease that evolves with no recognizable symptoms until the cancer is well advanced.
Along
with NSCLC, our pipeline of immuno-oncology therapies includes multiple hard-to-treat cancers.
Our
most recent orphan drug designation for THIO, granted in 2023, is for malignant gliomas, which include glioblastoma, the most aggressive
and most common type of brain cancer with only limited treatment options. THIO’s potent anticancer activity has been observed in
diffuse intrinsic pontine glioma (DIPG), one of the most aggressive and treatment-resistant brain tumors affecting the central nervous
system in children.
Multiple
tumor types including small cell lung cancer, liver cancer, and colorectal cancer will be studied in a second Phase 2 go-to-market trial,
THIO-102, to evaluate THIO with checkpoint inhibitors in these indications.
3
Cyramza® + docetaxel; REVEL Study: https://cyramza.lilly.com/hcp/nsclc-treatment/revel-trial-safety
Second
Generation Telomere Targeting Agents
Our
second-generation telomere targeting program is engaged in research and development for new drugs derived from THIO. We have developed
more than 80 THIO-like compounds to date, with three U.S. patent applications. Preclinical studies of several of these agents have shown
highly significant anti-cancer efficacy at low dose levels in multiple in vivo and in vitro models, warranting further investigation
as our next generation of telomere targeting candidates.
Next
Horizons
Our
key targeted milestones for THIO this year are THIO-101 progression-free survival (PFS) and THIO-101 duration of response (DoR), both
of which represent major clinical inflection points.
We
will soon engage with the FDA to align on the optimal trajectory to obtain commercial approval, with multiple paths under consideration.
We anticipate a final decision on THIO from the FDA in 2026.
In
closing, we deeply appreciate your interest and support of our clinical research and trials.
As
we move forward, we plan to pursue the FDA’s accelerated approval program for THIO, saving significant time and costs in our research,
and most importantly, bringing advanced NSCLC patients earlier access to our novel new anticancer therapy. We couldn’t be more
enthusiastic about the future for MAIA and look forward to sharing our continuing progress in 2024 and beyond.
Sincerely,
Vlad
Vitoc, M.D.
Chairman
and Chief Executive Officer
Forward
Looking Statements
MAIA
cautions that all statements, other than statements of historical facts contained in this letter to shareholders, are forward-looking
statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or
our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated
by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,”
“expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,”
“intend,” “future,” “potential,” or “continue,” and other similar expressions are intended
to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For
example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies
and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies,
(iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product
candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the
size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations
regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking
statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable,
are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good
faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees
of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ
materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it
was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information,
future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,”
“we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
Exhibit
99.2
MAIA
Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders
| |
● |
THIO-101
Phase 2 trial nears completion with survival and response data forthcoming; exploration of multiple cancer indications and next-generation
molecules continues |
| |
● |
Shareholder
Letter available in Investor Relations section of MAIA’s corporate website. |
CHICAGO,
IL – March 05, 2024 – MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”),
a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today published a 2024 Letter to Shareholders
by Chairman and Chief Executive Officer Vlad Vitoc, M.D., detailing the Company’s immuno-oncology cancer treatment candidates
and development pipeline.
“At
MAIA Biotechnology, our tenacious pursuit of innovative medicines to improve and extend people’s lives has led us to the forefront
of cancer research. As we wrap up the Phase 2 clinical trial of our lead molecule THIO in non-small cell lung cancer (NSCLC) and pursue
additional indications and a pipeline of next-generation THIO-like molecules, we are creating a robust and transformational cancer treatment
franchise,” states Dr. Vitoc at the opening of his shareholder letter.
Letter
Highlights
| |
● |
THIO-101
Phase 2 clinical trial nears completion; survival and response data updates forthcoming. |
| |
● |
Along
with NSCLC, MAIA’s pipeline of immuno-oncology therapies includes multiple hard-to-treat cancers. |
| |
● |
More
than 80 THIO-like compounds have been developed for the Company’s second-generation telomere targeting program. |
| |
● |
Company’s
pipeline includes THIO-102 Phase 2 and THIO-103 Phase 2/3 clinical trials (planning stage), and Investigational New Drug (IND)-enabling
studies for second-generation telomere targeting agents. |
MAIA’s
letter to shareholders is available at ir.maiabiotech.com.
About
MAIA Biotechnology, Inc.
MAIA
is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with
novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is
THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive
cancer cells. For more information, please visit www.maiabiotech.com.
Forward
Looking Statements
MAIA
cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements.
Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s
actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements.
The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,”
“plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,”
“future,” “potential,” or “continue,” and other similar expressions are intended to identify forward
looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements
we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and
development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing
or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates
and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth
potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our
ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking
statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable,
are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good
faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees
of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ
materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it
was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information,
future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,”
“we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
Investor
Relations Contact
+1
(872) 270-3518
ir@maiabiotech.com
v3.24.0.1
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
